Vitamin D in psoriasis
Trial question
What is the effect of vitamin D supplementation on psoriasis severity in patients with lower-range serum 25-hydroxyvitamin D levels?
Study design
Single center
Double blinded
RCT
Population
Characteristics of study participants
38.0% female
62.0% male
N = 122
122 patients (46 female, 76 male).
Inclusion criteria: adult patients with active plaque psoriasis and 25-hydroxyvitamin D levels < 24 ng/mL.
Key exclusion criteria: nut allergy; primary hyperparathyroidism; granulomatous diseases; pregnancy; clinical signs of proximal myopathy.
Interventions
N=60 vitamin D (cholecalciferol oral capsules, 100,000 IU loading dose, followed by 20,000 IU per week for 4 months).
N=62 placebo (matching placebo oral capsules for 4 months).
Primary outcome
Reduction in psoriasis area severity index score
0.34 points
0.41 points
0.4 points
0.3 points
0.2 points
0.1 points
0.0 points
Vitamin
D
Placebo
No significant
difference ↔
No significant difference in reduction in psoriasis area severity index score (0.34 points vs. 0.41 points; AD -0.11 points, 95% CI -0.45 to 0.23).
Secondary outcomes
No significant difference in reduction in self-administered psoriasis area severity index (0.5 vs. -0.25; AD 0.6 , 95% CI -0.55 to 1.76).
No significant difference in improvement in dermatology life quality index (-0.59 vs. 0.1; AD -0.86 , 95% CI -1.9 to 0.19).
No significant difference in improvement in physical global assessment score of 1 (8.5% vs. 11.5%; OR 0.66, 95% CI 0.27 to 1.63).
Conclusion
In adult patients with active plaque psoriasis and 25-hydroxyvitamin D levels < 24 ng/mL, vitamin D was not superior to placebo with respect to reduction in psoriasis area severity index score.
Reference
Marita Jenssen, Anne-Sofie Furberg, Rolf Jorde et al. Effect of Vitamin D Supplementation on Psoriasis Severity in Patients With Lower-Range Serum 25-Hydroxyvitamin D Levels: A Randomized Clinical Trial. JAMA Dermatol. 2023 May 1;159(5):518-525.
Open reference URL